Alpha Cognition Inc
ACOG
Pozycja w akcjach
#20413
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Cena akcji
$8.13
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$126.27M
Zmiana (1 dzień)
-3.79%
Zmiana (1 rok)
61.63%
Kraj
US
Handel Alpha Cognition Inc (ACOG)
Kategoria
Healthcare
EPS dla Alpha Cognition Inc (ACOG)
EPS na dzień June 2026 TTM: $-0.40
Według najnowszych raportów finansowych i ceny akcji firmy Alpha Cognition Inc, obecny EPS (TTM) wynosi $-0.40. Na koniec roku 2022 firma miała EPS w wysokości $-0.18, spadek w porównaniu do do EPS z roku 2021, który wynosił $-0.37.
Historia EPS dla Alpha Cognition Inc od 2018 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-0.40 | 166.67% |
| 2023 | $-0.15 | -16.67% |
| 2022 | $-0.18 | -51.35% |
| 2021 | $-0.37 | -61.46% |
| 2020 | $-0.96 | 357.14% |
| 2019 | $-0.21 | 672.06% |
| 2018 | $-0.03 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -4,430.00% |
US
|
|
| $-7.98 | 1,895.00% |
US
|
|
| $-5.29 | 1,222.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,035.00% |
NL
|
